Protagen Applying UNIarray Platform for Biogen's MS Drug Research

Under the terms of an agreement, Protagen's UNIarray platform will be used to retrospectively analyze samples from a Biogen clinical trial in order to find predictive and response biomarkers in relapsing remitting MS.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.